In this report we highlight the major health outcomes and achievements related to Health Protection NSW's activities in 2012, including some examples of health protection projects done in the field (Boxes 1-6). The health outcomes described in this report are measured mainly through routine surveillance data that are derived from notifications of selected diseases provided by doctors, hospitals and laboratories to Public Health Units under the NSW Public Health Act 2010. Tables 1-6 show disease-specific data on notifiable conditions reported by: year of onset of illness; month of onset of illness; Local Health District; and age group and sex. Note that the degree to which notification data reflect the true incidence of disease varies and is subject to a range of caveats. 1 
Surveillance

Vaccine-preventable diseases
In 2012 there were: • no haemophilus influenzae type b notifications in children aged less than 5 years for the first time since 1993 • 5824 pertussis notifications (including one death in a 7-week old infant), a marked decrease from the record numbers in 2011 (.13 000)
• 172 measles notifications, of which two were imported from overseas, 169 were found to be linked to an imported case (measles virus D8), while another was locally acquired but presumably acquired from an imported case not identified through surveillance (measles virus B3). Most cases were notified by South Western Sydney and Western Sydney Local Health Districts. People of Pacific Islander ethnicity and Aboriginal people were disproportionately affected. There were 58 notifications in children aged less than 5 years, with 37 notifications in infants aged less than 1 year (too young to be vaccinated) • 66 meningococcal disease notifications, the lowest number since the introduction of the meningococcal C vaccine in 2003. Of these, 43 were due to serogroup B (65%), five were due to serogroup Y (8%), four were due to serogroup W135 (6%), two were due to serogroup C (3%), and 12 were of an unknown serogroup (18%). The two cases of meningococcal C disease were reported in young adults who were not vaccinated. Meningococcal notifications have been declining for more than a decade • 105 mumps notifications, an increase from the 67 reported in 2011. The highest notifications were in metropolitan areas and in under-vaccinated persons aged 30-34 years (n ¼ 27), followed by those aged 35-39 years (n ¼ 15) • 566 invasive pneumococcal disease notifications, a slight increase compared with 529 in 2011. Serotype 19A was identified as the cause of infection in 33% of cases in children aged less than 5 years and 17% of the remainder of the cases where typing was available.
Bloodborne viruses
In 2012 there were:
• 2328 total hepatitis B case notifications, an 8% decrease compared with 2011 (n ¼ 2525) and the lowest recorded number in 20 years (total notifications are mainly of people whose time of infection is unknown). Fifty-four percent of cases were male and 30% were aged between 25 and 34 years • 409 cases of newly-diagnosed HIV infection, a 24% increase compared with 2011 (n ¼ 330). The increase was across most at-risk groups. Most new HIV infections were reported to be male homosexually-acquired (81%), with other risk exposure categories reported as heterosexual contact (14%) and injecting drug use (2%).
The proportion of people with newly-diagnosed homosexually-acquired HIV infection who reported having an HIV test in the year prior to diagnosis decreased slightly from 42% in 2011 to 40% in 2012, while the proportion of those who reported no previous HIV test prior to diagnosis rose from 14% in 2011 to 17% in 2012.
Box 4. Avian influenza in Hunter New England
An outbreak of low pathogenicity H9N2 at a Hunter New England turkey farm in April 2012 was the first such outbreak detected in Australian poultry. Eight human contacts were provided with seasonal influenza vaccination and placed under surveillance until 7 days after last poultry exposure. All remained well and baseline serology demonstrated no evidence of influenza A infection. Antivirals were not used. All birds were destroyed.
Enhanced surveillance by the Department of Primary Industries subsequently identified low pathogenicity H9N2 in a second turkey flock in Hunter New England. There was no significant poultry illness and repeat testing confirmed clearance of the virus from the flock. Six human contacts were encouraged to have seasonal influenza vaccination through their general practitioner and were monitored; none developed significant illness. Nose and throat swabs collected from two contacts with mild upper respiratory symptoms were positive for rhinovirus and enterovirus. Serology was not collected and antivirals were not used. No clear pathway of transmission between farms was identified and the same virus was later identified in water birds in the region.
In November, highly pathogenic H7N7 was detected in poultry on an egg farm in the region. Seven close human contacts were monitored and the offer of antiviral prophylaxis was accepted by one. Nose and throat swabs from a contact with upper respiratory symptoms tested negative for influenza and other respiratory pathogens by polymerase chain reaction. No other illness developed. All birds were destroyed.
The need for modified public health responses to low pathogenicity avian influenza outbreaks (rather than adopting high pathogenicity avian influenza protocols), with a limited role for serology and questionable value of antivirals during these outbreaks, were important lessons arising from the management of these avian influenza outbreaks.
Box 5. Public health emergency preparedness exercises
Sourcing ciprofloxacin for 200 people? Identifying the cause of a mysterious illness affecting children in the state's southwest? These fictional scenarios, considered as part of discussion exercises focused on an intentional release of anthrax spores (August 2012) and a contaminated consumer product (December 2012), are one of the best ways to test response arrangements, build relationships and identify planning gaps. In 2012 Health Protection NSW and the Office of the Chief Health Officer launched a series of exercises focused on public health responses to major incidents or emergencies. Health Protection NSW, the NSW Ministry of Health, Public Health Unit staff, and colleagues from other health specialities (e.g. pharmaceutical services, microbiology and toxicology) were brought together to tackle some of the trickier aspects of the myriad of incidents managed by public health services. The discussions, while always entertaining, also contribute to a common understanding of the tools and strategies we have at our disposal.
In the spirit of strengthening NSW Health's ability to deal with major emergencies and natural disasters, the Office of the Chief Health Officer led the development of a pilot specialised public health commander course. Following a competitive tender process, the course was developed in consultation with key public health practitioners and delivered to 21 participants over 3 days in June 2012. The aim of the course was to enhance the ability of senior NSW public health professionals to effectively lead teams during responses to emergencies or major incidents. The course enabled participants to interact with a range of existing emergency management tools and processes that are available for use in both emergency situations and day-to-day operations. The course also reinforced existing emergency management concepts and arrangements, including how to apply an incident control system.
Sexually transmissible infections
• 21 291 chlamydia case notifications, a 4% increase compared with 2011 (n ¼ 20 570 • 13 point-source outbreaks of Salmonella Typhimurium infection affecting 162 people, most likely associated with the consumption of sauces and desserts prepared with raw eggs.
Respiratory diseases
• 61 Legionnaires' disease case notifications due to Legionella pneumophila infection, compared with 60 cases in 2011. Public health investigations did not identify any common sources for these cases. L. pneumophila cases peaked in February 2012 with 12 cases reported. Notifications due to L. longbeacheae infection decreased (29 compared with 38 cases in 2011) • 7999 notifications of influenza, an increase compared with 5773 notifications in 2011. Approximately 78% of laboratory-confirmed influenza was influenza A, with the influenza A(H3N2) strain predominating (97%). The incidence of influenza B increased later in the season and accounted for 21% of laboratory-confirmed influenza cases overall. While laboratory-confirmed influenza notifications are likely to represent only a small proportion of cases in the community, other indicators of increased influenza activity in 2012 were: an increase from June to September of people presenting to emergency departments with influenza-like illness (well above the normal expected range); and a marked increase in the number of reported outbreaks of respiratory illness in aged-care and other residential care facilities. The increase in morbidity due to influenza is most likely because the predominant strain (influenza A (H3N2)/Victoria/361/2011) was different to the strain in the 2012 influenza vaccine • 471 notifications of tuberculosis, a decrease from the 523 cases reported in 2011 • three cases of multi-drug resistant tuberculosis (MDR-TB). Five cases per year were reported in 2010 and 2011.
Box 6. Investigating Legionnaires' disease clusters in western Sydney
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Vectorborne diseases
• 603 Ross River virus infection notifications, an increase from 579 in 2011 • 347 Barmah Forest virus infection notifications, a 24% decrease compared with the 458 notifications in 2011 • 208 dengue fever case notifications, a 50% increase compared with the 139 notifications in 2011. The majority of the cases in 2012 were linked to international travel; Indonesia was the most commonly reported exposure site (40%), followed by Thailand (21%), India (7%) and the Philippines (5%). While there currently is no local transmission of dengue fever in NSW, it is the most common mosquitoborne viral disease of humans worldwide and represents a major international public health concern • 70 malaria case notifications, compared with 77 in 2011. All were acquired overseas. Travel to India was the most commonly reported exposure site (19%), followed by Sudan and Pakistan (both 10%) • no confirmed cases of flavivirus infections, Kunjin virus infections or Murray Valley encephalitis virus infections notified • two confirmed cases of Chikungunya, both acquired outside Australia (India and Kenya); this is a decrease from the 10 cases notified in 2011.
Zoonotic diseases
In 2012 there was: • a slight decrease in Q fever case notifications (116 compared with 137 in 2011). Q fever was the most commonly notified zoonotic disease in 2012 • a slight decrease in brucellosis infections (four compared with six in 2011). Two cases were overseasacquired and two infections were in hunters of feral pigs in Northern NSW.
Prevention activities Immunisation
In 2012 NSW Health:
• maintained high immunisation coverage rates for children at 1, 2 and 5 years of age ( Workers to work collaboratively with existing services to promote timely vaccination of Aboriginal children through targeted interventions • developed an immunisation awareness campaign to inform the community and providers about the importance of ensuring that children are fully vaccinated on time • successfully implemented the transition from Prevenar 7 to Prevenar 13 vaccine for children at 2, 4 and 6 months of age, and a supplementary program for children who had commenced Prevenar 7 vaccination to provide greater protection against pneumococcal disease • introduced a more focused pertussis control strategy by offering new mothers free pertussis vaccine in the maternity unit after the birth of their child or via their general practitioner (GP) within 2 weeks post-birth • increased immunisation coverage rates for adolescents in the NSW School-Based Vaccination Program for vaccines offered to students in Years 7 and 10 ( 
Heat
In November 2012, when a period of unseasonably hot weather coincided with a number of major events in Sydney, the NSW Heatwave Sub Plan was activated for the first time. NSW Health worked closely with the NSW Police Force and other agencies to ensure the public were provided with clear and consistent advice on how to minimise the risk of heat-related illness.
Implementation of Public Health Regulation 2012
In 2012 Health Protection NSW: • developed supporting resources including forms, information sheets, fact sheets and audit tools to assist in the implementation of the Public Health Act 2010 and the Public Health Regulation 2012, both of which commenced on 1 September 2012 • held forums at 11 localities across the state to brief Local Government environmental health officers on the regulatory changes, and their implementation and enforcement methodology. Specific case studies were developed through a steering committee for presentation and study at the forums. Local Government feedback was positive, providing advice for improvements.
Asbestos
In 2012 Health Protection NSW:
• participated in the Heads of Asbestos Coordination Authority, a state-based interagency group that has been developing programs including a statewide plan for asbestos, a model asbestos policy for local councils, and a comprehensive public awareness campaign. Through this membership it also provides input into the newly formed Commonwealth Asbestos Safety and Eradication Agency.
Air quality
• supported two environmental studies in the Hunter Valley to help define the types of exposure of the community to particulate air pollution and determine the distribution and relative contribution of various sources to this pollution. This information will inform programs to reduce community exposure • supported the Chief Health Officer's Air Pollution Expert Advisory Committee, which provides independent advice on the scientific basis for management of the health effects of air pollution.
Conclusion
Communicable diseases and the environment pose many potential threats to human health. These potential threats are dealt with through a combination of four goals:
• preventing production of the threat (through, for example, immunisation, regulation of drinking water and working with planning agencies to ensure planning approvals address potential health threats) • early identification of the threat (through surveillance systems such as the disease and exposure notification, and arbovirus surveillance systems)
• reducing the level of the threat (through strategies such as outbreak control, immunisation, and identification and treatment of the causes of diseases) • effective communication (with the community, with appropriate health professionals, with other government agencies such as the NSW Environment Protection Authority and NSW Department of Planning, and with other jurisdictions, to respond to threats and reduce exposures).
Effective health protection for the NSW population is dependent on our success in achieving these four goals.
That success is dependent on the skills, experience and advocacy of health protection workers across the state in identifying, responding to and communicating health threats to the NSW population.
Increasing international travel also increases the risk of importing enteric diseases such as hepatitis A, typhoid and paratyphoid, and other vaccine-preventable diseases such as measles and diphtheria. This underlines the need to maintain high vaccination coverage rates for all NSW children, and for all people planning travel, to ensure they have received all their routine vaccines, as well as specific travel vaccines such as hepatitis A and typhoid for some destinations.
Steady migration to Australia of people from countries with a high burden of tuberculosis necessitates maintenance of specialised tuberculosis services accessible across NSW for early detection, expert treatment and screening activities.
